The third case is: - you control only a fraction of the ongoing-treatment market, and the windfall you could get as a monopolist in the short-lived cure market

The third case is: - you control only a fraction of the ongoing-treatment market, and the windfall you could get as a monopolist in the short-lived cure market is worth losing out on that steady cash flow